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studies on patient
comprehension—systematic review
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Abstract
Background: Informed consent is a basic concept of contemporary, autonomy-based medical practice and
facilitates a shared decision-making model for relations between physicians and patients. Thus, the extent to which
patients can comprehend the consent they grant is essential to the ethical viability of medicine as it is pursued
today. However, research on patients’ comprehension of an informed consent’s basic components shows that their
level of understanding is limited.
Methods: Systemic searches of the PubMed and Web of Science databases were performed to identify the
literature on informed consent, specifically patients’ comprehension of specific informed consent components.
Results: In total, 14 relevant articles were retrieved. In most studies, few clinical trial participants correctly
responded to items that examined their awareness of what they consented to. Participants demonstrated the
highest level of understanding (over 50%) regarding voluntary participation, blinding (excluding knowledge about
investigators’ blinding), and freedom to withdraw at any time. Only a small minority of patients demonstrated
comprehension of placebo concepts, randomisation, safety issues, risks, and side effects.
Conclusions: We found that participants’ comprehension of fundamental informed consent components was low,
which is worrisome because this lack of understanding undermines an ethical pillar of contemporary clinical trial practice
and questions the viability of patients’ full and genuine involvement in a shared medical decision-making process.
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Introduction
Written informed consent (IC) is considered a basic
principle of medical practice. It provides information
and shares knowledge between the physician and patient
and creates a shared-decision-based healthcare plan [1].
In this regard, the IC should implement a principle of
autonomy, by which a patient’s right to deliberately de-
cide for herself whether to accept or refuse the offered
treatment must be respected [2, 3]. However, patients’
adequate understanding of the provided information is a
major limitation.
Within its ethical and legal foundations, the informed
consent process is pivotal to supporting ethically sound
medical intervention. However, obtaining adequately
informed consent from patients is complex because it
requires human interactions involving discussion of
several elements, such as the patient’s condition and
therapeutic options, including risks and benefits, incon-
veniences, and uncertainties. In this regard, IC must
include both a form that patients are required to read
and sign, and oral communication to ensure adequate
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understanding to facilitate voluntary willingness to
participate in a clinical trial [4].
Major barriers to adequate IC understanding include
the patients’ subjective impression that they are well
informed and physicians’ over-confidence in the intelligi-
bility and quality of the information they provide to pa-
tients. Nonetheless, the concept of respecting patients’
autonomy in medical research is based on the assump-
tion that the informed consent process actually leads to
patients’ full comprehension of what they are consenting
to. Unless this assumption is demonstrably true, the eth-
ical viability of the current medical experimentation
practice is seriously flawed.
Given that most available studies focused on informed
consent obtained for the purpose of clinical trials, we
limited our scope to this kind of research practice.
However, there is no reason to assume that the level of
understanding of informed consent granted by patients
in a routine medical practice is significantly higher than
that in clinical trials. On the contrary, we find it plaus-
ible that patients recruited to clinical trials are relatively
better informed and physicians may explain the nature
of a research intervention and participation conditions
more thoroughly. Therefore, it is improbable that pa-
tients’ actual comprehension of consent in standard
medical practice is higher than in the relatively better
examined conditions of clinical trials, and there are
reasons to expect that it is lower. With this reservation,
our conclusions may be extended beyond clinical trial
conditions to the more general practice of obtaining
informed consent in medical practice.
Therefore, we systematically reviewed the available
literature on patients’ actual (rather than declared) un-
derstanding of what they consented to, with particular
interest in questionnaires developed to objectify patients’
understanding of the consent content, rather than their
subjective impression on how well informed they were
during the consenting process, and whether they were
satisfied with the way in which their consent was obtained.
Methods
We performed a systematic review using the Preferred
Reporting Items for Systematic Review and Meta-Analysis
(PRISMA) criteria [5]. The electronic search to identify
and capture informed consent literature was conducted
between October 2019 and January 2020. We queried
PubMed and Web of Science databases using the follow-
ing search terms: “informed consent [mh] AND (compre-
hension [mh] OR perception [mh] OR knowledge [mh]
OR decision making [mh] OR understanding OR commu-
nication [mh]) AND (randomised controlled trials as topic
[mh] OR clinical trial as topic [mh])”. No year restrictions
were applied. To make the search as comprehensive as
possible, we used the Boolean operators “AND” and “OR”
to link the search terms.
Inclusion criteria were (a) studies assessing comprehen-
sion of IC, (b) English-language articles in peer-reviewed
academic/scientific journals, (c) full-text articles available
electronically, and (d) articles with available questionnaires
used to examine the level of patients’ understanding.
Exclusion criteria were (a) studies comparing or evaluat-
ing methods of informed consent not related to IC com-
prehension (defined in inclusion criteria), (b) studies that
used intervention to improve patients’ understanding, (c)
studies that included patients with cognitive decline, (d)
qualitative research, (e) articles based on patients’ impres-
sion of understanding, (f) studies based on interviews, (g)
studies that did not provide the questionnaire used, (h)
conference abstracts, and (i) animal studies.
We included only articles that examined knowledge
about the information included in the IC. In this regard,
we excluded articles based on interviews and question-
naires that examined only patients’ impressions of un-
derstanding (e.g. “Did you receive adequate information
about the study?”).
Article selection was performed independently by the
first (TP) and second (KS) authors. Database searches
were completed in a blinded manner using identical
search terms. After identifying eligible articles, any
doubts were resolved during a meeting to review the
queried article(s) against the inclusion and exclusion
criteria. The final selection of eligible articles included in
the critical appraisals was made based on the agreement
between TP and KS.
Results
Selection process
The study selection process is shown in Fig. 1. In total,
4263 articles were retrieved from the databases, of which
14 were included in the review based on the inclusion/ex-
clusion criteria (Table 1). The number of participants varied
across studies, ranging from 29 [16] to 1835 [9]. In most
studies (n = 12), participants were adults [7–15, 17–19];
three studies examined parents or guardians [6, 10, 16]; and
one study included both adult patients and parents or
guardians [10]. Medical specialties included infectious
disease in 42% (n = 6), including vaccine studies in 21% (n
= 3), oncology in 28% (n = 4); rheumatology in 21% (n = 3);
neurology in 7% (n = 2), and others in 7%. Two studies in-
cluded clinical trials in more than one specialty [8, 15].
Most studies examined IC-related questions that covered
compensation, withdrawal criteria and consequences, study
versus treatment, study administration, and randomisation.
Understanding of informed consent
Questionnaires that examined participants’ understanding
of IC components included true/false items [9, 10, 18],
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multiple choice items, and the Quality of Informed Con-
sent survey [7, 11]. Questionnaires differed in the number
of items and content. All questionnaires examined partici-
pants’ recall of IC content, except one, where participants
used the IC text to find the answers to the survey ques-
tions [19]. Additionally, the elapsed time between partici-
pants’ experience of the informed consent process and
their IC research participation ranged from before the
actual IC [18] process to 5 years after the IC [15]; four
studies did not report this measure [8, 12, 16, 19].
Three studies examined participants’ understanding of
the research purpose. Schumacher et al. reported that all
participants understood that they were participating in a
research study and recognised its purpose [7]. In the
remaining two studies, most participants comprehended
the study aims (70–90%) [9, 19].
Voluntary participation was examined in seven studies
[6–9, 11, 13, 14]. Bergenmar et al. reported the highest
level of comprehension, with 96% of participants com-
prehending the voluntary nature of their participation
[11]. In contrast, Chu et al. reported the lowest level of
comprehension, with 53.6% [8]. Additionally, Krosin
et al. noted a significant difference between urban and
rural participants, with 85% and 21%, respectively, show-
ing comprehension of the voluntary nature of participa-
tion [13]. Chu et al. reported that 53.6% patients
understood that physicians should not persuade them to
participate in a study [8]. Criscione et al. reported that
10% of participants indicated that their personal doctor
would mind if they dropped out of the study [14].
Freedom to withdraw was reported in eight studies
[6–8, 10, 12, 14, 17, 19], which was a relatively well-
comprehended IC component, with the lowest level of
63% reported by Criscione et al. [14]. Ponzio et al. re-
ported that all participants correctly understood their
right to withdraw at any time [19]. Additionally, one study
reported on awareness of withdrawal consequences, with
44% demonstrating comprehension of this point; and
withdrawal criteria, with only 10% showing comprehen-
sion [13].
Comprehension of randomisation was investigated in
seven studies, with Harrison’s study reporting the high-
est level of understanding (96%), and Bertoli et al.
reporting the lowest (10%) [8, 11, 12, 14–16]. Similarly,
the understating of placebo and active treatment ranged
from 13% [15] to 97% [9]. Differences by specialty
regarding comprehension of the placebo concept were
noted by Pope et al., with the lowest comprehension
reported in the ophthalmology group (13%) and the
highest in the rheumatology group (49%) [15].
Risks and benefits were explored in nine [6, 7, 9–11,
13, 14, 18, 19] and three studies [6, 7, 19], respectively.
Krosin et al. reported that only 7% of patients compre-
hended risks associated with involvement in clinical
trials [13]. In contrast, in one group, all patients (who
could use the IC text to find questionnaire answers)
were aware of potential side effects and risks of the
treatment [19]. Ponzio et al. reported the highest
between-group differences in the comprehension of
study benefits, which ranged from 35.5 to 96.6%,
Fig. 1 Selection process for eligible articles
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depending on whether participants were successful in
finding the answer in the IC text [19].
It is worth noting that Schumacher et al. reported that
patients were not aware that the proposed treatment
was experimental and not standard therapy [7]. Add-
itionally, only 20% of participants understood that the
benefits of treatment were uncertain and that participa-
tion was associated with additional risks. Similarly, over
30% of patients were not aware that alternative treat-
ments were available.
Furthermore, Chu et al. found that only 43.4% of
patients understood that they would not be reimbursed
for all adverse events related to the study. Of note, the au-
thors did not specify the conditions regarding reimburse-
ment. The number of correct responses was higher in the
healthy control group than in the patient group (excluding
the last question related to reimbursement) [8].
Finally, Bertoli et al. reported that 86 participants
(83.5%) recalled that they had fully read the informed
consent form, while 11.7% had partially read it and 9%
did not remember to what extent they had read it. Inter-
estingly, most patients (51.4%) rated their knowledge
about the study as high, but objective evaluation of par-
ticipants’ knowledge showed that only 14.3% demon-
strated a high level of knowledge, and 58.1% and 27.6%
showed intermediate and low knowledge, respectively
[12]. Pope et al. reported that 18% of participants admit-
ted that they had not fully read the study information
letter and 10% admitted that they were afraid to ask
questions [15].
Assessment of risk of bias
Studies included in this review were either randomised
nor blinded for the outcomes related to IC. Therefore,
the assessment of risk of bias was not possible [20].
Discussion
We concluded that there are significant discrepancies in
research participants’ understanding of voluntary partici-
pation, blinding, and freedom to withdraw. Only rarely
did all participants respond correctly to questionnaire
items, indicating that they actually comprehended what
they consented to. We found that participants presented
the highest level of understanding (over 50%) about vol-
untary participation, blinding (excluding knowledge
about investigators’ blinding), and freedom to withdraw
at any time. Further, our results suggest that only a small
minority of patients had a clear and accurate under-
standing of all aspects of their consent. In particular,
patients presented significant difficulties in grasping the
concept of placebo randomisation, safety, risks, and side
effects [7–16, 18, 19]. Additionally, some patients had very
limited comprehension of the research benefits [6, 19].
Our findings are consistent with the results of previous
meta-analyses on the quality of the informed consent
process in clinical trials [21]. However, in general, pa-
tients included in our review demonstrated lower levels
of comprehension. Tam et al. [21] reported that two-
thirds of participants (the highest reported level) under-
stood the freedom to withdraw from a study at any time,
followed by the nature of the study, the voluntary nature
of participation, and the potential benefits. In contrast,
our results showed that 69.6% of participants understood
the purpose of the study and only 54.9% could name at
least one risk. Finally, approximately half of the partici-
pants understood placebo and randomisation concepts.
However, in contrast to our review, Tam et al. included
data from interviews in their analysis. Surprisingly, in
58.5% of interviews, participants could not establish
whether the interviewers were investigators in the ori-
ginal clinical trial and, as such, could influence the re-
sults [21]. In a previous systematic review of clinical
trial IC or surgery IC, Falagas et al. concluded that only
50% of participants properly understood all IC compo-
nents [22].
These findings demonstrate that crucial information,
including risks and benefits, voluntariness, and the rela-
tion of trials to standard therapy, are not actually com-
prehended by a substantial number of participants. This
seriously undermines the present practice of providing a
sound ethical basis for experimenting with human sub-
jects. Moreover, it seems that patients’ understanding of
specific IC components has not changed over the past
20 years [21]. The guidelines for good clinical practice in
trials, introduced by the World Health Organization
20 years ago, have not affected patients’ comprehen-
sion [21, 23].
It is natural to expect a correlation between general
health literacy and comprehension of information rele-
vant to informed consent. The extent to which deficits
in understanding consent depend on insufficient general
health literacy remains to be examined. However, this
may not be crucial to the existing practice viability in
obtaining informed consent as a safeguard for respecting
patients’ autonomy in clinical trials. It is inevitable that
patients recruited for clinical trials will have varying edu-
cation and health literacy levels. There is no reason to
assume that patients included in clinical trials have
lower than average health literacy. Therefore, the out-
comes suggest that, in the daily practice of clinical trials,
patients with diverse education and health literacy levels
agree to participate in medical testing based on defect-
ive, or at least incomplete, comprehension of the rele-
vant information. This suggests that the present routines
regarding patients’ autonomy (and thus—dignity) in clin-
ical trials are ethically questionable, if not explicitly
flawed.
Pietrzykowski and Smilowska Trials           (2021) 22:57 Page 6 of 8
None of the studies included in our review directly
examined relations between patients’ health literacy and
their level of comprehension regarding the consent they
granted. However, Chaisson et al. reported that patients’
education was considered as a factor potentially influencing
their understanding of the consent. They administered
questionnaires in English or Setswana and concluded that
participants who had a higher education level or chose to
complete the questionnaires in English rather than
Setswana demonstrated better overall comprehension.
Similarly, Schumacher et al. and Krosin et al. found signifi-
cant correlations between comprehension scores and for-
mal education levels [7, 13]. Ellis et al. distributed a survey
to adult participants in the USA and Mali, plus the parents
or guardians of a child in an additional group of Mali par-
ticipants. Within Malian adults, only 9% signed the IC,
while the remaining 91% provided a fingerprint. In the
Malian parents or guardians group, 84% provided a finger-
print rather than a signature. The literacy rate for parents
or guardians varied between sites, ranging from 3 to 17%.
Of note, the questionnaire was initially intended to teach
participants rather than to collect data [10]. The re-
searchers found that patients’ literacy was not a significant
factor in their ability to understand the consent they were
asked to grant.
The studies included in this review have some limita-
tions that should be considered while interpreting the
results. First, they demonstrated a high level of hetero-
geneity in sample size and type of underlying medical
condition. We speculate that this may also have influ-
enced patients’ understanding of informed consent. For
example, Pope et al. reported significant differences in
the level of understanding within patients recruited to
rheumatology, ophthalmology, and cardiology studies
[15]. Similarly, Chu et al. reported that 61% of healthy
controls were recruited from phase I trials, in which they
were under the close monitoring and care of the re-
searchers, while 80.8% of patients were recruited from
phase III or IV trials that were conducted in outpatient
clinics [8]. Second, especially in oncology, the presumed
potential benefit of a novel treatment may exceed the
presumed risk of the study, biasing patients towards
consenting to participate in the trial despite a limited
understanding of its experimental nature. Third, al-
though education level was usually mentioned, health
literacy was not examined in most studies. Additionally,
other factors related to underlying disease may influence
patients’ comprehension, including fatigue, depression,
cognitive status, and emotional factors associated with
study inclusion and doctor’s office visits. The resulting
scope of interference with patients’ ability to grasp the
full meaning of the consent remains unexamined. However,
such factors should be considered when assessing the
current practice of obtaining informed consent. Finally, the
scales used to examine patients’ understanding differed
across studies and ranged from multiple choice to Likert-
like scale items, which limited our ability to adequately
compare patients’ understanding across studies.
In many cases, patients may be unaware that they lack
understanding and therefore do not ask for clarification.
In some cases, the information on expected therapeutic
benefits may overshadow other aspects of the project,
making patients less receptive to technical or more dis-
couraging sides of the trial. Interestingly, our findings sug-
gest that mothers asked to consent to including their
children in a clinical trial were more determined to com-
prehend all relevant information than adult patients decid-
ing on their own involvement in a trial. However, this is
based on the results from a single study in this review [6].
The relatively consistent series of empirical findings
opens further questions that have not been satisfactorily
addressed in the literature to date. We hypothesise that
patients seriously overrate their own level of comprehen-
sion. The extent to which they mistakenly feel that they
have understood all relevant information while, in fact,
they miss many important aspects of the consent present
an interesting question that we are preparing to investi-
gate. Similarly, physicians may seriously overrate their
patients’ level of comprehension based on (1) their own
efforts to effectuate patients’ understanding, (2) their
confidence in patients’ declaration of understanding and
satisfaction, and (3) their own health literacy influencing
their belief that the information offered to patients is
easier to understand than is actually the case.
Thus, further research should target empirical testing of
the hypothesised discrepancies between (1) the actual level
of understanding by patients regarding what they consented
to, (2) their subjective confidence that they understood
what they consented to, and (3) physicians’ confidence that
their patients actually understood what they consented to.
Noting the scarcity of analogous research on the actual
understanding of consent by patients in regular thera-
peutic practice, we recommend that future studies
examine such comprehension in ordinary medical set-
tings rather than only through the context of clinical tri-
als. Since physicians typically take more care and effort
to explain all relevant aspects of a clinical trial, we as-
sume that, in a standard therapeutic setting, lack of
comprehension regarding consent may be even larger.
Therefore, a lack of relevant research in therapeutic clin-
ical settings constitutes a remarkable gap in a crucial as-
pect of ethically viable medical practice.
Conclusion
We found that the level of comprehension regarding in-
formed consent components, such as voluntary participation,
blinding, and freedom to withdraw, was low, being under-
stood by only half of the patients. This seriously undermines
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the ethical foundations of current practices for obtaining
consent in clinical trials, potentially also challenging the
standard approach to safeguarding patients’ autonomy in or-
dinary medical settings.
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